Mattoli Sabrina
Center of Expertise in Research and Innovation of the International Network for the Advancement of Viable Applicable Innovations in Life Sciences (InAvail), Basel, Switzerland.
Avail Biomedical Research Institute, Munich, Germany.
Infect Dis Ther. 2021 Mar;10(1):27-34. doi: 10.1007/s40121-020-00394-3. Epub 2021 Jan 9.
The authorization for emergency use of a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been issued in diverse countries in December 2020, and additional vaccine candidates soon may be cleared for a similar emergency use. If it is reasonable to believe that in some Western countries most people may be vaccinated by the end of 2021, insufficient supplies, access inequities across countries, and deficiencies in enforcing the participatory engagement of communities will present important challenges for the achievement of sufficient vaccination coverage worldwide in less than 2-3 years. A possible strategy for bridging the gap until full vaccine deployment is based on the integration of improved non-pharmaceutical measures and recently authorized pharmaceutical interventions to reduce as much as possible hospitalizations and deaths in the coming months, when recurring infection peaks are expected.
2020年12月，多个国家已发布针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的紧急使用授权，很快可能会有更多候选疫苗获批用于类似的紧急使用。如果有理由相信在一些西方国家，到2021年底大多数人可能会接种疫苗，那么供应不足、国家间获取不平等以及社区参与执行方面的缺陷，将对在不到两到三年的时间内实现全球足够的疫苗接种覆盖率构成重大挑战。在全面部署疫苗之前弥合差距的一种可能策略是，整合改进的非药物措施和最近授权的药物干预措施，以在未来几个月预计反复出现感染高峰时尽可能减少住院和死亡人数。
